Metastatic Gastric Cancer Clinical Trials

10 recruiting

Metastatic Gastric Cancer Trials at a Glance

14 actively recruiting trials for metastatic gastric cancer are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Beijing, Middletown, and Commack. Lead sponsors running metastatic gastric cancer studies include CNBG-Virogin Biotech (Shanghai) Ltd., Fudan University, and Akeso.

Browse metastatic gastric cancer trials by phase

Treatments under study

About Metastatic Gastric Cancer Clinical Trials

Looking for clinical trials for Metastatic Gastric Cancer? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Gastric Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Gastric Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting

A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)

Locally Advanced Unresectable or Metastatic Gastric Cancer
Akeso610 enrolled1 locationNCT07547787
Recruiting
Phase 1

A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors

Metastatic Breast CancerEndometrial CancerAdvanced Solid Tumor+6 more
Institut Paoli-Calmettes27 enrolled1 locationNCT05143970
Recruiting
Phase 2

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Metastatic Breast CancerBreast NeoplasmsGastroesophageal Junction Adenocarcinoma+7 more
Seagen, a wholly owned subsidiary of Pfizer172 enrolled139 locationsNCT06157892
Recruiting
Phase 4

Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer

Breast CancerEsophageal CancerMetastatic Gastric Cancer
University of Michigan Rogel Cancer Center22 enrolled1 locationNCT05183126
Recruiting
Phase 2

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Metastatic Gastric AdenocarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaUnresectable Gastric Adenocarcinoma+10 more
Memorial Sloan Kettering Cancer Center37 enrolled7 locationsNCT06251973
Recruiting
Phase 2

Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

Gastroesophageal Junction AdenocarcinomaMetastatic Gastric CancerAdvanced Gastric Cancer
Jiangsu HengRui Medicine Co., Ltd.351 enrolled2 locationsNCT07102901
Recruiting
Not Applicable

Cytoreductive Gastrectomy After Systemic Therapy Versus Systemic Therapy Alone For Limited Metastasis Gastric Cancer

Gastric CancerMetastatic Gastric CancerSystemic Therapy+1 more
University Medical Center Ho Chi Minh City (UMC)250 enrolled1 locationNCT06768463
Recruiting
Phase 1

BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.

Gastroesophageal Junction AdenocarcinomaAdvanced or Metastatic Gastric Cancer
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.80 enrolled1 locationNCT06773312
Recruiting
Phase 2

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Metastatic Gastric CancerUnresectable Gastric CarcinomaHER2-positive Gastric Cancer
Qilu Hospital of Shandong University110 enrolled20 locationsNCT06730373
Recruiting

Liver Embolization Approaches for Tumor Management

CholangiocarcinomaHepatocellular CarcinomaMetastatic Cancer+4 more
IRCCS San Raffaele580 enrolled1 locationNCT05714124
Recruiting
Phase 2

Sintilimab Plus FOLFIRI as Salvage Therapy for Patients With Advanced Gastric Cancer

Unresectable/Metastatic Gastric Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University40 enrolled1 locationNCT06365008
Recruiting
Phase 3

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Locally Advanced Unresectable or Metastatic Gastric CancerLocally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
FutureGen Biopharmaceutical (Beijing) Co., Ltd486 enrolled1 locationNCT06177041
Recruiting
Phase 2

Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer

Gastroesophageal-junction CancerGastroesophageal Junction AdenocarcinomaMetastatic Cancer+6 more
Fudan University55 enrolled1 locationNCT06121700
Recruiting
Phase 1Phase 2

Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer

Metastatic Gastric Cancer
CNBG-Virogin Biotech (Shanghai) Ltd.43 enrolled1 locationNCT06008925